Progenity is developing a rule-out test for preeclampsia to give healthcare providers an additional clinical assessment tool for use with patients showing signs and symptoms of preeclampsia.

Unmet Need

Preeclampsia is the #2 cause of
maternal mortality.1
Learn more.

Healthcare Cost

This disease creates an economic burden
for the healthcare system.
Learn more.

Clinical Dilemma & Solution

Current methods cannot differentiate preeclampsia
from other hypertensive disorders.
Learn more.

Unmet Need

Preeclampsia is a hypertensive condition of pregnancy that usually occurs in the second half of pregnancy.
This condition is primarily defined by its symptoms:

  • New onset hypertension (high blood pressure)
  • Hypertension is often accompanied by new onset proteinuria (protein in the urine)
  • Additional presentations in absence of proteinuria may include visual disturbances, headaches, epigastric (upper abdomen) pain, vomiting, thrombocytopenia (low platelet count), renal insufficiency (poor kidney function), pulmonary edema (excess fluid in the lungs), and sudden edema (swelling) of face, hands, or feet

According to the Preeclampsia Foundation, preeclampsia occurs in 5% to 8% of pregnancies in the United States, and it is one of the leading causes of premature birth and maternal and neonatal morbidity and mortality. The syndrome has a 1.5- to 2.0-fold higher incidence in first pregnancies, and contributes to 15% of maternal deaths and 25% of perinatal/neonatal deaths.

Healthcare Cost

Preeclampsia has a significant impact on patient outcomes, which comes at a cost to the US healthcare system.

In a collaboration between Progenity and Geisinger, a large regional healthcare system, >2,100 mother/infant pairs were matched and evenly distributed among three cohorts of normal, hypertensive, and preeclamptic pregnancies. Primary data from Geisinger’s electronic medical and billing records was used to estimate differences in healthcare costs.

  • Preeclamptic pregnancies were on average $28,603 more costly than normal pregnancies and $17,608 more costly than hypertensive pregnancies (2015 U.S. dollars).2
  • The mean infant cost in the preeclamptic pregnancies was $28,898, almost 8 times greater than for the normal cohort of $3,669 and more than double the hypertension cohort of $12,648 (2015 U.S. dollars).2
  • The healthcare costs of preeclampsia are significant and primarily driven by high infant costs linked to premature delivery (3 weeks earlier compared to normal and more than 2 weeks earlier for hypertension) and other adverse events. Additionally, women with preeclampsia had higher rates of C-section deliveries and maternal adverse events.2

This research was presented at the Society for Maternal-Fetal Medicine (SMFM) Annual Pregnancy Meeting. Read the poster here.

Clinical Dilemma and Solution

More than 700,000 women present with symptoms of preeclampsia each year.3,4,5 However, current methods cannot differentiate preeclampsia from other hypertensive disorders that may occur during pregnancy. There is a substantial unmet clinical need to identify symptomatic patients who are not at risk of developing preeclampsia. Ruling out preeclampsia in these patients has the potential to reduce unnecessary interventions, up to and including preterm delivery, leading to decreased healthcare costs and improved patient outcomes.

Progenity is developing a noninvasive, highly sensitive, multi-analyte blood-based test designed to assist healthcare providers in the clinical assessment and medical care of pregnant women presenting with signs and symptoms of preeclampsia.

With high sensitivity and a high negative predictive value (NPV), the test is designed to provide physicians with a novel adjunctive laboratory assessment to help identify those patients without the disease, and allow them to focus management on those patients who are more likely to develop preeclampsia.

Potential benefits of this test:

  • Better patient stratification
    Rule out patients without preeclampsia
  • Optimized patient management
    Reduce need for more frequent monitoring and diagnostics
  • Lower healthcare costs
    Avoid unnecessary hospitalizations and interventions
  • Improved patient care
    Avoid unnecessary preterm induction, which can lead to adverse outcomes

Learn more

To learn more about preeclampsia, and other hypertensive disorders of pregnancy through the Preeclampsia Foundation visit

  1. Henderson JT, et al. Preeclampsia Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2017 Apr 25;317(16):1668-1683.
  2. Hao et al. Economic Burden of Preeclampsia: Maternal and Infant Healthcare Costs. Poster presented at Society for Maternal-Fetal Medicine (SMFM) Annual Pregnancy Meeting 2019. Las Vegas, NV.
  3. Ananth CV, et al. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ. 2013 Nov 7;347:f6564.
  5. Center for Disease Control and Prevention. Births: Final Data for 2018 (In press).